Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C T Ritchlin

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Annals of the Rheumatic Diseases|August 8, 2008
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)P J Mease, P Ory, J T Sharp, et al.
Annals of the Rheumatic Diseases|October 28, 2008
Treatment recommendations for psoriatic arthritisC T Ritchlin, A Kavanaugh, D D Gladman, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Annals of the Rheumatic Diseases|August 8, 2008
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)P J Mease, P Ory, J T Sharp, et al.
Annals of the Rheumatic Diseases|October 28, 2008
Treatment recommendations for psoriatic arthritisC T Ritchlin, A Kavanaugh, D D Gladman, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
Pageof 2